Alhubaishi, Alaa A., Alsharekh, Lolwa M., Almoharb, Haya F., Alqarni, Faisal A., Alqahtani, Abdalhadi M., Alghazwni, Mohammed K., Alfuraydi, Modhi A., Alsadi, Abdulmajed Z., Altalhi, Raad Y., Almutairi, Tariq M., and Alshehri, Ghadah H.
Objectives: To assess clinicians' adherence to fingolimod's effective use according to the prescribed recommendations to reduce safety risk, identify the consequences, and highlight areas for improvement to policy makers for the benefit of both patient and care-giver. Methods: A retrospective observational study conducted at a tertiary hospital targeting multiple sclerosis patients on fingolimod from January 2017 to December 2021. The physicians' adherence to the manufacturer's instructions was assessed and categorized into good, moderate, and poor based on adherence to fingolimod instructions and monitoring measures. Four monitoring measures were assessed: bradycardia observation, ophthalmic examination, liver enzymes, and infections. In addition, the impact of adherence on patient safety was also assessed. Results: A total of 140 patients were included. Seventy-two patients (51.4%) had physician with poor adherence followed only one instruction or none). Sixty-five patients (46.4%) had 2-3 manufacture recommendations where physician's adherence was moderate. Three patients (2.10%) had all manufacturer's recommendations. In terms of fingolimod complications, 18 patients found to have bradycardia after the first does, macular oedema and infections was reported in 4 patients, and the elevation in hepatic enzymes was reported in 6 patients. Poor physician's adherence has resulted in treatment incompleteness and highest fingolimod discontinuation or switching to other treatment options. Conclusion: Adherence to fingolimod instructions was poor among physicians which resulted in highest drug switching or discontinuing rate. [ABSTRACT FROM AUTHOR]